Barclays PLC Amgen Inc Transaction History

Barclays PLC

$288 Billion
Q1 2024

A detailed history of Barclays PLC transactions in Amgen Inc stock. As of the latest transaction made, Barclays PLC holds 432,400 shares of AMGN stock, worth $135 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

432,400

Previous 2,916,227 85.17%

Holding current value

$135 Million

Previous $840 Million 85.36%

% of portfolio

0.04%

Previous 0.31%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$268.87 - $324.56 $384 Million - $463 Million	1,426,434 Added 48.91%	4,342,661 $1.23 Billion
Q4 2023 Feb 15, 2024	BUY	$255.7 - $288.46 $354 Million - $400 Million	1,385,762 Added 90.55%	2,916,227 $840 Million
Q3 2023 Nov 07, 2023	SELL	$218.65 - $271.46 $34.9 Million - $43.4 Million	-159,722 Reduced 9.45%	1,530,465 $411 Million
Q2 2023 Aug 03, 2023	BUY	$214.27 - $253.37 $191 Million - $226 Million	890,242 Added 111.29%	1,690,187 $375 Million
Q1 2023 May 04, 2023	SELL	$225.79 - $275.2 $208 Million - $254 Million	-921,588 Reduced 53.53%	799,945 $193 Million

Q4 2022 Feb 13, 2023	BUY	$229.03 - $291.01 $164 Million - $208 Million	714,274 Added 70.91%	1,721,533 $452 Million
Q3 2022 Nov 03, 2022	BUY	$224.46 - $253.15 $36.7 Million - $41.4 Million	163,726 Added 19.41%	1,007,259 $227 Million
Q2 2022 Aug 12, 2022	SELL	$230.71 - $256.74 $97 Million - $108 Million	-420,372 Reduced 33.26%	843,533 $205 Million
Q1 2022 May 16, 2022	SELL	$219.27 - $242.57 $388 Million - $429 Million	-1,769,873 Reduced 58.34%	1,263,905 $306 Million
Q4 2021 Feb 14, 2022	BUY	$198.88 - $227.6 $196 Million - $224 Million	984,406 Added 48.03%	3,033,778 $683 Million
Q3 2021 Nov 09, 2021	BUY	$212.27 - $248.7 $125 Million - $146 Million	586,707 Added 40.11%	2,049,372 $436 Million
Q2 2021 Aug 13, 2021	BUY	$233.58 - $259.14 $53 Million - $58.8 Million	226,790 Added 18.35%	1,462,665 $357 Million
Q1 2021 May 13, 2021	BUY	$221.91 - $258.6 $58.9 Million - $68.7 Million	265,594 Added 27.37%	1,235,875 $308 Million
Q4 2020 Feb 11, 2021	BUY	$216.38 - $257.67 $21.3 Million - $25.4 Million	98,667 Added 11.32%	970,281 $223 Million
Q3 2020 Nov 12, 2020	BUY	$234.65 - $260.95 $28.5 Million - $31.7 Million	121,433 Added 16.19%	871,614 $222 Million
Q2 2020 Aug 12, 2020	SELL	$197.81 - $242.74 $23.6 Million - $28.9 Million	-119,190 Reduced 13.71%	750,181 $177 Million
Q1 2020 May 13, 2020	SELL	$182.24 - $241.7 $109 Million - $144 Million	-596,754 Reduced 40.7%	869,371 $176 Million
Q4 2019 Feb 10, 2020	SELL	$189.21 - $243.2 $20.9 Million - $26.9 Million	-110,649 Reduced 7.02%	1,466,125 $353 Million
Q3 2019 Nov 14, 2019	SELL	$174.11 - $208.62 $69.3 Million - $83.1 Million	-398,116 Reduced 20.16%	1,576,774 $305 Million
Q2 2019 Aug 14, 2019	BUY	$166.7 - $195.41 $108 Million - $126 Million	645,704 Added 48.58%	1,974,890 $364 Million
Q1 2019 May 15, 2019	BUY	$180.87 - $203.88 $13.2 Million - $14.9 Million	73,123 Added 5.82%	1,329,186 $253 Million
Q4 2018 Feb 14, 2019	SELL	$178.4 - $208.25 $26.1 Million - $30.4 Million	-146,047 Reduced 10.42%	1,256,063 $245 Million
Q3 2018 Nov 14, 2018	SELL	$185.29 - $208.89 $1.77 Million - $1.99 Million	-9,535 Reduced 0.68%	1,402,110 $291 Million
Q2 2018 Aug 14, 2018	SELL	$166.05 - $186.51 $148 Million - $166 Million	-889,143 Reduced 38.65%	1,411,645 $261 Million
Q1 2018 May 15, 2018	BUY	$169.43 - $198.0 $129 Million - $151 Million	762,949 Added 49.61%	2,300,788 $392 Million
Q4 2017 Feb 14, 2018	BUY	$168.79 - $188.59 $56.6 Million - $63.2 Million	335,122 Added 27.86%	1,537,839 $267 Million
Q3 2017 Nov 14, 2017	BUY	$167.29 - $191.0 $201 Million - $230 Million	1,202,717	1,202,717 $224 Million

Others Institutions Holding AMGN

# of Institutions

2,931

Shares Held

401M

Call Options Held

6.59M

Put Options Held

6.6M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $167B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account